Cargando…

Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial

BACKGROUND: Paracetamol’s solubility is achieved by adding to the excipient sodium salts, either as bicarbonate, carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it has raised a hypothesis that may interfere with the control of that ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Benitez-Camps, Mencia, Vinyoles-Bargalló, Ernest, Rebagliato-Nadal, Oriol, Morros-Pedrós, Rosa, Pera-Pujadas, Helena, Dalfó-Baqué, Antoni, López-Pavón, Ignacio, Roca-Sánchez, Carlos, Coma-Carbó, Rosa Maria, De La Figuera Von Wichmann, Mariano, Mengual-Martínez, Lucas, Yuste-Marco, Carmen, Teixidó-Colet, Montserrat, Pepió i Vilaubí, Josep M., Ciurana-Tost, Riera, Pou-Vila, Rosa, Vila-Coll, Ma Antònia, Bordas-Julve, Josep Maria, Aragonès-Forès, Rosa, Pelegrina-Rodríguez, Francisco Javier, Agudo-Ugena, Josep, Blanco-Mata, Carlos, de la Iglesia Berrojalbiz, Jon, Burgos-Alonso, Natalia, Gómez-Fernández, Maria Cruz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676099/
https://www.ncbi.nlm.nih.gov/pubmed/26654907
http://dx.doi.org/10.1186/s12872-015-0161-7
_version_ 1782405110532407296
author Benitez-Camps, Mencia
Vinyoles-Bargalló, Ernest
Rebagliato-Nadal, Oriol
Morros-Pedrós, Rosa
Pera-Pujadas, Helena
Dalfó-Baqué, Antoni
López-Pavón, Ignacio
Roca-Sánchez, Carlos
Coma-Carbó, Rosa Maria
De La Figuera Von Wichmann, Mariano
Mengual-Martínez, Lucas
Yuste-Marco, Carmen
Teixidó-Colet, Montserrat
Pepió i Vilaubí, Josep M.
Ciurana-Tost, Riera
Pou-Vila, Rosa
Vila-Coll, Ma Antònia
Bordas-Julve, Josep Maria
Aragonès-Forès, Rosa
Pelegrina-Rodríguez, Francisco Javier
Agudo-Ugena, Josep
Blanco-Mata, Carlos
de la Iglesia Berrojalbiz, Jon
Burgos-Alonso, Natalia
Gómez-Fernández, Maria Cruz
author_facet Benitez-Camps, Mencia
Vinyoles-Bargalló, Ernest
Rebagliato-Nadal, Oriol
Morros-Pedrós, Rosa
Pera-Pujadas, Helena
Dalfó-Baqué, Antoni
López-Pavón, Ignacio
Roca-Sánchez, Carlos
Coma-Carbó, Rosa Maria
De La Figuera Von Wichmann, Mariano
Mengual-Martínez, Lucas
Yuste-Marco, Carmen
Teixidó-Colet, Montserrat
Pepió i Vilaubí, Josep M.
Ciurana-Tost, Riera
Pou-Vila, Rosa
Vila-Coll, Ma Antònia
Bordas-Julve, Josep Maria
Aragonès-Forès, Rosa
Pelegrina-Rodríguez, Francisco Javier
Agudo-Ugena, Josep
Blanco-Mata, Carlos
de la Iglesia Berrojalbiz, Jon
Burgos-Alonso, Natalia
Gómez-Fernández, Maria Cruz
author_sort Benitez-Camps, Mencia
collection PubMed
description BACKGROUND: Paracetamol’s solubility is achieved by adding to the excipient sodium salts, either as bicarbonate, carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it has raised a hypothesis that may interfere with the control of that risk factor. Therefore, the objective of this study is to evaluate the effect on blood pressure of effervescent paracetamol compared to non-effervescent, in hypertensive patients. METHODS/DESIGN: This is the protocol of a phase IV multicenter clinical trial, randomized, controlled, crossover, open, which will compare the effect of two different formulations of paracetamol (effervescent or non-effervescent) in the blood pressure of hypertensive patients, with a seven weeks follow up. 49 controlled hypertensive patients will be included (clinical BP lower than 150 and 95 mmHg, and lower than 135 mmHg and 85 mmHg in patients with diabetes or a history of cardiovascular event, and daytime ambulatory measurements lower than 140 and 90 mmHg) and mild to moderate pain (Visual Analog Scale between 1 and 4). The study was approved by the ethics committee of the Fundació Jordi Gol i Gurina and following standards of good clinical practice. The primary endpoint will be the variations in systolic BP in 24 h Ambulatory Blood Pressure Monitoring, considering significant differences 2 or more mmHg among those treated with non-effervescent and effervescent formulations. Intention-to-treat and per-protocol analysis will be held. DISCUSSION: Despite the broad recommendation not to use effervescent drugs in patients with hypertension, there are relatively little studies that show exactly this pressor effect due to sodium in salt that gives the effervescence of the product. This is the first clinical trial designed to study the effect of effervescence compared to the non-effervescent, in well-controlled hypertensive patients with mild to moderate pain, performed in routine clinical practice TRIAL REGISTRATION: NCT 02514538
format Online
Article
Text
id pubmed-4676099
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46760992015-12-12 Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial Benitez-Camps, Mencia Vinyoles-Bargalló, Ernest Rebagliato-Nadal, Oriol Morros-Pedrós, Rosa Pera-Pujadas, Helena Dalfó-Baqué, Antoni López-Pavón, Ignacio Roca-Sánchez, Carlos Coma-Carbó, Rosa Maria De La Figuera Von Wichmann, Mariano Mengual-Martínez, Lucas Yuste-Marco, Carmen Teixidó-Colet, Montserrat Pepió i Vilaubí, Josep M. Ciurana-Tost, Riera Pou-Vila, Rosa Vila-Coll, Ma Antònia Bordas-Julve, Josep Maria Aragonès-Forès, Rosa Pelegrina-Rodríguez, Francisco Javier Agudo-Ugena, Josep Blanco-Mata, Carlos de la Iglesia Berrojalbiz, Jon Burgos-Alonso, Natalia Gómez-Fernández, Maria Cruz BMC Cardiovasc Disord Study Protocol BACKGROUND: Paracetamol’s solubility is achieved by adding to the excipient sodium salts, either as bicarbonate, carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it has raised a hypothesis that may interfere with the control of that risk factor. Therefore, the objective of this study is to evaluate the effect on blood pressure of effervescent paracetamol compared to non-effervescent, in hypertensive patients. METHODS/DESIGN: This is the protocol of a phase IV multicenter clinical trial, randomized, controlled, crossover, open, which will compare the effect of two different formulations of paracetamol (effervescent or non-effervescent) in the blood pressure of hypertensive patients, with a seven weeks follow up. 49 controlled hypertensive patients will be included (clinical BP lower than 150 and 95 mmHg, and lower than 135 mmHg and 85 mmHg in patients with diabetes or a history of cardiovascular event, and daytime ambulatory measurements lower than 140 and 90 mmHg) and mild to moderate pain (Visual Analog Scale between 1 and 4). The study was approved by the ethics committee of the Fundació Jordi Gol i Gurina and following standards of good clinical practice. The primary endpoint will be the variations in systolic BP in 24 h Ambulatory Blood Pressure Monitoring, considering significant differences 2 or more mmHg among those treated with non-effervescent and effervescent formulations. Intention-to-treat and per-protocol analysis will be held. DISCUSSION: Despite the broad recommendation not to use effervescent drugs in patients with hypertension, there are relatively little studies that show exactly this pressor effect due to sodium in salt that gives the effervescence of the product. This is the first clinical trial designed to study the effect of effervescence compared to the non-effervescent, in well-controlled hypertensive patients with mild to moderate pain, performed in routine clinical practice TRIAL REGISTRATION: NCT 02514538 BioMed Central 2015-12-10 /pmc/articles/PMC4676099/ /pubmed/26654907 http://dx.doi.org/10.1186/s12872-015-0161-7 Text en © Benitez-Camps et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Benitez-Camps, Mencia
Vinyoles-Bargalló, Ernest
Rebagliato-Nadal, Oriol
Morros-Pedrós, Rosa
Pera-Pujadas, Helena
Dalfó-Baqué, Antoni
López-Pavón, Ignacio
Roca-Sánchez, Carlos
Coma-Carbó, Rosa Maria
De La Figuera Von Wichmann, Mariano
Mengual-Martínez, Lucas
Yuste-Marco, Carmen
Teixidó-Colet, Montserrat
Pepió i Vilaubí, Josep M.
Ciurana-Tost, Riera
Pou-Vila, Rosa
Vila-Coll, Ma Antònia
Bordas-Julve, Josep Maria
Aragonès-Forès, Rosa
Pelegrina-Rodríguez, Francisco Javier
Agudo-Ugena, Josep
Blanco-Mata, Carlos
de la Iglesia Berrojalbiz, Jon
Burgos-Alonso, Natalia
Gómez-Fernández, Maria Cruz
Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
title Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
title_full Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
title_fullStr Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
title_full_unstemmed Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
title_short Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
title_sort evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676099/
https://www.ncbi.nlm.nih.gov/pubmed/26654907
http://dx.doi.org/10.1186/s12872-015-0161-7
work_keys_str_mv AT benitezcampsmencia evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT vinyolesbargalloernest evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT rebagliatonadaloriol evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT morrospedrosrosa evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT perapujadashelena evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT dalfobaqueantoni evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT lopezpavonignacio evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT rocasanchezcarlos evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT comacarborosamaria evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT delafigueravonwichmannmariano evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT mengualmartinezlucas evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT yustemarcocarmen evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT teixidocoletmontserrat evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT pepioivilaubijosepm evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT ciuranatostriera evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT pouvilarosa evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT vilacollmaantonia evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT bordasjulvejosepmaria evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT aragonesforesrosa evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT pelegrinarodriguezfranciscojavier evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT agudougenajosep evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT blancomatacarlos evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT delaiglesiaberrojalbizjon evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT burgosalonsonatalia evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial
AT gomezfernandezmariacruz evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial